Glutamate-evoked redox state alterations are involved in tissue transglutaminase upregulation in primary astrocyte cultures  by Campisi, A. et al.
FEBS Letters 578 (2004) 80–84 FEBS 29004Glutamate-evoked redox state alterations are involved in
tissue transglutaminase upregulation in primary astrocyte culturesA. Campisia, D. Caccamob, G. Li Voltia, M. Currob, G. Parisib, R. Avolac,
A. Vanellaa, R. Ientileb,*
aDepartment of Biological Chemistry, Medical Chemistry and Molecular Biology, University of Catania, V.le A. Doria, 6, 95100 Catania, Italy
bDepartment of Biochemical, Physiological and Nutritional Sciences, University of Messina, Via Consolare Valeria, Policlinico Universitario,
98125 Messina, Italy
cDepartment of Chemical Sciences, Section of Biochemistry, University of Catania, V.le A. Doria, 6, 95100 Catania, Italy
Received 11 August 2004; revised 4 October 2004; accepted 29 October 2004
Available online 8 November 2004
Edited by Vladimir SkulachevAbstract The aim of this study was to evaluate the involvement
of oxidative stress in glutamate-evoked transglutaminase
(TGase) upregulation in astrocyte cultures (14 DIV). A 24 h
exposure to glutamate caused a dose-dependent depletion of
glutathione intracellular content and increased the ROS pro-
duction in cell cultures. These eﬀects were receptor-mediated, as
demonstrated by inhibition with GYKI 52466. The pre-incuba-
tion with glutathione ethyl ester or cysteamine recovered
oxidative status and was eﬀective in signiﬁcantly reducing
glutamate-increased tissue TGase. These data suggest that
tissue TGase upregulation may be part of a biochemical response
to oxidative stress induced by a prolonged exposure of astrocyte
cultures to glutamate.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Transglutaminases (TGases) are a family of calcium-de-
pendent enzymes that catalyze an acyl transfer reaction be-
tween peptide-bound glutamine residues and primary amines.
This in turn can result in the e-(c-glutamyl) lysine cross-linking
of proteins or their poly-amination, with consequent protein
conformational changes. Several ﬁndings have demonstrated
that the upregulation of tissue type of TGases (tTG) was in-
volved in diﬀerent pathological conditions associated with
neurodegenerative diseases [1–3]. However, a possible role for
the high levels of enzyme activity in cell damage, or the pro-
posed implication in the tissue response to external injury, is
not yet clear. Although it has been reported that the tran-
samidating activity of tTG is regulated by several factors, in-
cluding Ca2þ, GTP, retinoids, nitric oxide, and* Corresponding author. Fax: +39-90-2213898.
E-mail address: ientile@unime.it (R. Ientile).
Abbreviations: GSH/GSSG, reduced/oxidised glutathione; GYKI
52466, 1-[4-aminophenyl]-4-methyl-7,8-methylenedioxy-5H-2,3-benzo-
diazepine; LDH, lactate dehydrogenase; MTT, 3-(4,5-dimethyl-2-thi-
azolyl)-2,5-diphenyl tetrazolium bromide; ROS, reactive oxygen
species; TGase, transglutaminase; tTG, tissue transglutaminase
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underlying neuronal cell damage has not been completely
understood.
Previously, we demonstrated that glutamate receptor-medi-
ated events upregulated tTG in cerebellar granule cells as well
as in cultured astrocytes [8,9]. Elevated extracellular glutamate
levels have been shown to aﬀect neuronal functions, mainly by
activation of speciﬁc ionotropic and metabotropic receptors,
and have been demonstrated to be involved in the neuronal
loss associated with many neurological diseases [10,11]. Ad-
ditionally, increasing evidence suggests a gliotoxic action of
extracellular glutamate for astroglial cells. In particular, it has
been reported that, in diﬀerentiated astrocytes, a brief expo-
sure to glutamate causes cell swelling, whereas a prolonged
incubation induces cell damage, resulting from calcium over-
load and reactive oxygen species (ROS) production [12–14].
The mechanisms of this toxicity involve alterations in gluta-
mate transport, glutathione depletion, and macromolecular
synthesis [13]. Consequently, several calcium-dependent en-
zymes may be activated, causing mitochondria impairment,
decrease in ATP levels, and subsequent neuronal cell death
[12,15]. Recently, it has been demonstrated, in Swiss 3T3 ﬁ-
broblasts, that intracellular ROS were essential for the acti-
vation of tTG by both lysophosphatidic acid and TGF-b, and
this eﬀect was inhibited by the ROS scavengers [16]. Con-
versely, there is substantial evidence that a number of agents,
scavenging ROS and improving mitochondrial function,
ameliorate cell death in various models of neuronal damage
[17–19]. The present study was therefore aimed to investigate
the involvement of oxidative stress in the expression of gluta-
mate-evoked tTG in primary astrocyte cultures.2. Materials and methods
2.1. Materials
Cell culture medium and sera, TRIzol for RNA extraction and
Thermoscript RT-PCR system for cDNA synthesis, were from Invit-
rogen (Milano, Italy). Aprotinin, leupeptin, pepstatin, 3-(4,5-dimethyl-
2-thiazolyl)-2,5-diphenyl tetrazolium bromide (MTT), glutathione re-
duced (GSH) ethyl ester, cysteamine–HCl, and other chemicals of
analytical grade were obtained from Sigma (Milano, Italy). 1-[4-Ami-
nophenyl]-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine (GYKI
52466) was from Research Biochemicals Inc. (Natick, MA). RT-PCR
speciﬁc primers for diﬀerent rat TGase isoforms were synthesized byation of European Biochemical Societies.
A. Campisi et al. / FEBS Letters 578 (2004) 80–84 81Primm (Milano, Italy). Monoclonal tTG antibody CUB 7402 was
from LabVision Corp. (Fremont, CA). Horseradish peroxidase
(HRP)-conjugated secondary antibody was from Amersham Pharma-
cia Biotech (Milano, Italy).
2.2. Cell cultures
Primary cultures of astrocytes were prepared from newborn albino
rat brains (1–2-day-old Wistar strain) and checked for purity as pre-
viously described [9]. Cerebral tissues, after dissection and careful re-
moval of the meninges, were mechanically dissociated through sterile
meshes of 82-lm pore size (Nitex). Isolated cells were suspended in
Dulbecco’s modiﬁed Eagle’s medium supplemented with 20% (vol/vol)
heat-inactivated fetal bovine serum, 2 mM glutamine, streptomycin (50
lg/ml) and penicillin (50 U/ml), and plated at a density of 3 106 cells/
100-mm dish and of 0.5 105 cells/chamber of multichambered slides.
Cells were maintained at 37 C in a 5% CO2/95% air humidiﬁed at-
mosphere for two weeks and medium exchanged every three days. All
eﬀorts were made to minimize both the suﬀering and number of ani-
mals used. All experiments conformed to the guidelines of the Ethical
Committee of the University of Messina, Italy.
2.3. Glutamate treatment
Astrocytes at 14 days in vitro (DIV) were treated with glutamate (10–
500 lM) for 24 h as previously described [9]. In a subset of experiments
to assess the inhibition of glutamate eﬀects, cell cultures were pre-in-
cubated with either the speciﬁc AMPA/KA receptor antagonist, GYKI
52466 (100 lM), or GSH ethyl ester (50–100 lM), or cysteamine–HCl
(100–500 lM), which were added 30 min before glutamate exposure.
Four replicates were carried out for each sample.
2.4. Cytotoxicity assessment
Astrocyte survival analysis was performed by MTT reduction assay,
evaluating mitochondrial dehydrogenase activity. In brief, the culture
medium was removed and replaced with MTT solution. After incu-
bation at 37 C for 30 min, the MTT solution was removed and blue
purple formazan crystals dissolved in dimethylsulfoxide for colori-
metric quantiﬁcation at 570 nm by using a plate reader (Sunrise, Tecan
Italia, Cologno Monzese, Italy).
Lactate dehydrogenase (LDH) release was also tested to assess ne-
crotic cell death as described by Chen et al. [13].
2.5. Glutathione measurement
Cells were scraped oﬀ and lysed in 50 lM sodium phosphate buﬀer,
pH 7.4. The protein concentration in cell extracts was determined by
Bradford assay (Bio-Rad, Richmond, CA). Then, total glutathione
intracellular content (GSH+GSSG) was chemically determined ac-
cording to Chen et al. [13].
2.6. Evaluation of intracellular peroxide concentrations
To evaluate production of ROS, astrocyte cultures were treated with
20,70-dichloroﬂuorescein diacetate for 20 min, rinsed with serum-free
medium, and intracellular peroxide levels were measured for individual
cells in multiple cultures under ﬂuorescein optics, as previously de-
scribed [16].Fig. 1. Evaluation of intracellular GSH content in primary cultures of
astrocytes (14 DIV) exposed to glutamate. Cell cultures were incubated
for 24 h with glutamate (10–500 lM) (A); in presence or absence of
AMPA/KA receptor antagonist, GYKI 52466 (100 lM) (B); then,
GSH intracellular content was measured by a colorimetric assay as
reported in Section 2. * P < 0:05, ** P < 0:01 signiﬁcant diﬀerences
compared with the control.2.7. RT-PCR
Total RNA was isolated using TRIzol and reverse-transcribed us-
ing the Thermoscript RT-PCR kit according to the manufacturer’s
instructions. cDNA was ampliﬁed for 35 cycles with speciﬁc primers
for rat TGase 1, tTG, TGase 3, and b-actin (as reaction internal
control), using a Hybaid PCR Sprint thermocycler (Celbio; Milano,
Italy). RT-PCR products were separated on 2% agarose gel and
quantiﬁed by densitometric analysis with an AlphaImager 1200 Sys-
tem (Alpha Innotech, San Leandro, CA). Ampliﬁed cDNAs were
directly sequenced and sequences matched with known cDNA se-
quences of rat TGases.
2.8. Western blotting
Analysis of tTG expression in glutamate-exposed astrocytes, in the
presence or absence of externally added GSH ethyl ester (50–100 lM)
or cysteamine–HCl (100–500 lM), was performed with speciﬁc tTG
mouse antibody, CUB 7402, as reported by Ientile et al. [8]. Immu-
noblots were scanned and quantiﬁed by densitometric analysis with
AlphaImager 1200 System.2.9. Statistical analysis
All values are presented as meansS.E.M. Statistical analysis was
performed using one-way ANOVA, followed by Newman–Keuls post
hoc test.3. Results
First, we evaluated the glutamate-evoked oxidative stress by
measuring the depletion of intracellular GSH levels. Glutamate
(100–500 lM) produced a dose-dependent decrease in the in-
tracellular GSH levels below control levels. In particular, the
average GSH content was 13.8 2.2 nmol/mg of protein in
control cultures. The GSH dropped to 73.6% and 65.6% of the
control, after a 24 h exposure to 100 lMglutamate and 500 lM
glutamate, respectively (Fig. 1A). Consistent with previous
observations [9], the 24 h exposure of 14 DIV cultured as-
troglial cells to glutamate (100–500 lM) did not signiﬁcantly
aﬀect cell functions and viability, as revealed by the MTT re-
duction assay and LDH release measurement (data not shown).
The pre-incubation with GYKI 52466, the selective inhibitor
of KA/AMPA receptors, diminished glutamate eﬀects, indi-
cating the involvement of receptor-linked events in glutathione
decrease (Fig. 1B). Oxidative stress levels produced by
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cellular ROS production. Glutamate produced a signiﬁcant
increase (33%) of intracellular ROS in comparison with un-
treated control cultures (Fig. 2).
To directly assess the involvement of oxidative stress in the
expression of diﬀerent TGase isoforms in astroglial cells, we
evaluated the eﬀects of the most eﬀective concentration of
glutamate (500 lM), in the absence or presence of either GSH
ethyl ester or cysteamine–HCl, the latter able to increase GSH
content. Under our experimental conditions, tTG mRNA
transcript levels were strongly increased by 500 lM glutamate
in comparison to controls. Conversely, TGase 1 mRNA levels
were low in control cultures and were not signiﬁcantly aﬀected
in glutamate-treated astrocytes (Fig. 3). No evidence was ob-
tained for the presence of TGase 3 transcript.
The addition of GSH ethyl ester (50–100 lM) or cyste-
amine–HCl (100–500 lM), 30 min before glutamate exposure,
was able to reduce the increase in tTG expression induced by
glutamate. In particular, the most signiﬁcant eﬀects were ob-
served in the presence of 100 lM GSH ethyl ester or 500 lM
cysteamine–HCl. A partial inhibition of glutamate-induced
tTG upregulation was also obtained by pre-incubating astro-Fig. 2. Evaluation of ROS production in primary cultures of astrocytes
(14 DIV) exposed to glutamate. Cell cultures were incubated for 24 h
with glutamate (10–500 lM); then, changes in ROS production were
evaluated by ﬂow cytometric analysis, after treatment with DCFD.
* P < 0:05 signiﬁcant diﬀerences compared with the cultures in the
absence of glutamate.
Fig. 3. Analysis of glutamate eﬀects on TGase expression in astrocytes.
Cell cultures (14 DIV) were exposed to 500 lM glutamate for 24 h, in
the presence or absence of either glutamate receptor inhibitor, or an-
tioxidants. RT-PCR analysis of TGase 1, tTG and TGase 3 expression
was carried out. After 35 cycles of ampliﬁcation with speciﬁc primers,
mRNA transcripts were found only for tTG and, in lower amounts, for
TGase 1. Lane 1, control; lane 2, glutamate; lane 3, glutamate+GYKI
52466 (100 lM); lane 4, glutamate+ cysteamine (100 lM); lane 5,
glutamate+ cysteamine (500 lM); lane 6, glutamate+GSH ethyl ester
(50 lM); lane 7, glutamate+GSH ethyl ester (100 lM).cyte cultures with GYKI 52466 (100 lM), the selective an-
tagonist of AMPA/KA receptors (Fig. 3).
Western blot analysis of tTG expression conﬁrmed that this
was upregulated by glutamate injury, and that GSH ethyl
ester, in a concentration range 50–100 lM, reduced glutamate-
evoked increase in tTG. Analogous eﬀect was obtained by
pre-incubation with cysteamine–HCl, which, at 500 lM con-
centration, was able to counteract glutamate-dependent in-
crease in tTG (Fig. 4).
The pre-incubation of primary astrocyte cultures either with
the membrane permeant GSH delivery agent, GSH ethyl ester,
or with cysteamine–HCl, was able to counteract glutamate
eﬀects on ROS production and intracellular GSH depletion. In
particular, both compounds signiﬁcantly reduced glutamate-
dependent ROS increase, but only GSH ethyl ester (100 lM)
was able to restore ROS basal levels (Fig. 5A). However, GSH
ethyl ester (100 lM) or cysteamine–HCl (500 lM), in a similar
manner, almost completely prevented glutamate-induced GSH
depletion (Fig. 5B).4. Discussion
The present data indicate that stimulation of cultured as-
trocytes with high concentrations of glutamate results in oxi-
dative stress, as indicated by the reduction of GSH levels and
overproduction of intracellular ROS. However, GSH deple-
tion was not necessarily associated with alterations in cell vi-
ability, considering that glutamate at indicated doses, after 24
h exposure, did not produce cell damage. Indeed, the altered
redox status is consistent with a transporter-mediated toxicity
evoked by glutamate [12]. In accordance with other reports, it
is possible to suggest that glutamate uptake-induced impair-
ment of cystine/glutamate antiporter leads to depletion of
GSH content and biochemical alterations, resulting in the
delayed toxic eﬀect for primary astrocyte cultures [13,20].
The present results also extend previous observations on
TGase expression in primary astrocytes treated with gluta-
mate. In fact, we provided evidence that, under our conditions,
diﬀerent TGase isoforms are expressed, although a prolonged
exposure to 500 lM glutamate was able to signiﬁcantly aﬀect
only tTG protein expression. Indeed, the occurrence of a sig-
niﬁcant increase in tTG mRNA levels, more abundant than
TGase 1, is in agreement with previous observations demon-
strating that tTG upregulation was associated with in vitro as
well as in vivo models of cell stress response [16,21]. The
causative eﬀect of oxidative stress on the rises in tTG expres-
sion in astrocyte cultures was conﬁrmed by both inhibition of
ROS production and intracellular GSH depletion throughFig. 4. Western blot analysis of tTG expression. Immunoblotting of
tTG antigen was performed with speciﬁc monoclonal antibody. Lane
1, control; lane 2, glutamate (500 lM); lane 3, glutamate+ cysteamine
(100 lM); lane 4, glutamate+ cysteamine (500 lM); lane 5, gluta-
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Fig. 5. (A) Evaluation of ROS production in primary cultures of as-
trocytes (14 DIV), exposed to glutamate in the presence or absence of
externally added GSH ethyl ester or cysteamine–HCl. (B) Evaluation
of intracellular GSH content in primary cultures of astrocytes (14
DIV), exposed to glutamate in the presence or absence of cysteamine–
HCl or GSH ethyl ester. * P < 0:05 signiﬁcant diﬀerences compared
with the control.
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covery of redox status, achieved by these agents, was accom-
panied by a concomitant, dose-dependent, reduction of
glutamate-induced tTG upregulation. In this regard, the
greater eﬀect observed in the presence of GSH ethyl ester could
reside in its more powerful action, than cysteamine–HCl, in
restoring ROS control levels. It has been reported, in Swiss
3T3 ﬁbroblasts, that ROS are involved in the in situ activation
of TGase, and that intracellular Ca2þ may play an important
role to mediate this eﬀect [16]. Indeed, in astrocytes, alterations
of glutamate transport, induced by prolonged exposure to
glutamate, trigger increases in ROS production followed by
increases in calcium-dependent enzymes. Further, these eﬀects
can be reverted by antioxidants, such as GSH ethyl ester that
increases glutamate uptake and inhibits glutamate toxicity
lessening cell damage. Considering the inﬂuence of GSH de-
pletion or supplementation in the regulation of tTG expres-
sion, it is possible to propose that TGase reactions mediate
early changes in astrocyte cultures induced by a prolonged
exposure to glutamate. Indeed, several ﬁndings have demon-
strated that GSH levels in the brain were lowered in cerebral
ischemia [22,23] and that GSH depletion caused an enlarge-
ment of mitochondria in the brain [24]. Furthermore, an in-
creasing body of evidence suggests that mitochondriaalterations may be a key regulator of cell death [25] and mi-
tochondria swelling has been observed in early brain damage
[24,26]. In relation to this, it has been reported that alteration
in mitochondrial functions signiﬁcantly increases tTG activity
[27], suggesting that tTG-dependent hyperpolarization of mi-
tochondria can be considered as an important early event in
the biochemical changes evoked by oxidative stress [28].
However, further experiments must be carried out to provide
information on the regulatory mechanisms of TGase gene
transcription evoked by oxidative stress.
A remarkable bulk of experimental data has clearly indi-
cated that several neurodegenerative injuries are associated
with the excessive activation of glutamate receptors [11,29,30],
suggesting that pathways, other than excitotoxicity, may
contribute to cell vulnerability through altered glutamate
transport especially regarding astrocytes [31]. In various
models of brain wounds to adult rats, the astrocyte response
was characterized by increases in protein expression such as
glial ﬁbrillary acid protein and vimentin, and these alterations
were typical features in brain tissue from patients with neu-
rodegenerative diseases [32–34]. In this context, in several
neuropathological conditions, such as Alzheimer’s disease,
Parkinson’s disease, and amyotrophic lateral sclerosis, TGase
increases and the presence of cross-linked products may be
directly related to cell damage and neuronal loss [2,35]. Con-
sidering that excitotoxicity and oxidative stress are interde-
pendent phenomena, it is possible to hypothesize that TGase
upregulation may be a component of biochemical response to
oxidative stress triggered by glutamate receptor activation in
brain tissue.References
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